Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Retained Earnings (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Retained Earnings data on record, last reported at -$1.8 billion in Q4 2025.

  • For Q4 2025, Retained Earnings fell 54836.9% year-over-year to -$1.8 billion; the TTM value through Dec 2025 reached -$1.8 billion, down 54836.9%, while the annual FY2025 figure was -$1.8 billion, 54836.9% down from the prior year.
  • Retained Earnings reached -$1.8 billion in Q4 2025 per CLDX's latest filing, down from $3.8 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $3.8 million in Q3 2025 and bottomed at -$1.8 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$870.6 million, with a median of -$1.2 billion recorded in 2021.
  • Peak YoY movement for Retained Earnings: skyrocketed 100.25% in 2021, then crashed 1208877.68% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$1.1 billion in 2021, then dropped by 9.82% to -$1.3 billion in 2022, then dropped by 11.26% to -$1.4 billion in 2023, then surged by 100.24% to $3.3 million in 2024, then crashed by 54836.9% to -$1.8 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$1.8 billion in Q4 2025, $3.8 million in Q3 2025, and $3.3 million in Q2 2025.